<code id='507C875FAC'></code><style id='507C875FAC'></style>
    • <acronym id='507C875FAC'></acronym>
      <center id='507C875FAC'><center id='507C875FAC'><tfoot id='507C875FAC'></tfoot></center><abbr id='507C875FAC'><dir id='507C875FAC'><tfoot id='507C875FAC'></tfoot><noframes id='507C875FAC'>

    • <optgroup id='507C875FAC'><strike id='507C875FAC'><sup id='507C875FAC'></sup></strike><code id='507C875FAC'></code></optgroup>
        1. <b id='507C875FAC'><label id='507C875FAC'><select id='507C875FAC'><dt id='507C875FAC'><span id='507C875FAC'></span></dt></select></label></b><u id='507C875FAC'></u>
          <i id='507C875FAC'><strike id='507C875FAC'><tt id='507C875FAC'><pre id='507C875FAC'></pre></tt></strike></i>

          leisure time

          leisure time

          author:comprehensive    Page View:79
          Grail

          Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

          Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

          advertisement

          It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more
          Ambulance rides for just $100? Advisers want major billing fixes
          Ambulance rides for just $100? Advisers want major billing fixes

          AdobeApanelofgovernmentadvisersfinallyhasendorsedideasforCongresstosolvetheparticularlythornyproblem

          read more
          Malaria cases in Florida and Texas: Here’s what you need to know
          Malaria cases in Florida and Texas: Here’s what you need to know

          MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

          read more

          IVF, abortion rights issues kick off Biden’s State of the Union

          VicePresidentKamalaHarrisstandsasHouseSpeakerMikeJohnsonofLouisianawatchesasPresidentBidendeliversth